Latest Breaking News On - Joshuar lamstein - Page 3 : comparemela.com
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Scopus BioPharma Finalizes Arrangements for Submission of IND Package
Submission to FDA Expected in Q2 2021
News provided by
Share this article
NEW YORK, March 15, 2021 /PRNewswire/
Scopus BioPharma Inc. (Nasdaq: SCPS ) today announced the finalization of arrangements for the completion of the investigational new drug ( IND ) package for the company s lead drug candidate and its submission to the United States Food and Drug Administration ( FDA ). The IND submission is expected in Q2 2021.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Scopus BioPharma Announces Completion of Clinical Lot Manufacture
Manufactured Lot Fulfills Requirements for Planned Phase 1 Clinical Trial
Key milestone to enable finalization of IND package for submission to FDA
News provided by
Share this article
NEW YORK, Jan. 19, 2021 /PRNewswire/
Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin s lymphoma. This is a key milestone to enable finalization of the investigational new drug ( IND ) package for submission to the United States Food and Drug Administration ( FDA ).
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Scopus BioPharma Announces Appointment of Additional Directors
December 29, 2020 GMT
(PRNewsfoto/Scopus BioPharma Inc.)
NEW YORK, Dec. 29, 2020 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are delighted to be in a position to attract prominent industry leaders to our Board. Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.”
vimarsana © 2020. All Rights Reserved.